Andere talen Jazz Pharmaceuticals plc

Aandelen

JAZZ

IE00B4Q5ZN47

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
109,5 ^USD	+1,89%		-0,44%	-11,01%

02/04	Jazz Pharmaceuticals rondt licentieaanvraag af bij FDA voor behandeling van galwegkanker	MT
02/04	Jazz Pharmaceuticals rondt Zanidatamab Biologics License Application af voor eerder behandelde HER2-positieve uitgezaaide galwegkanker	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Jazz Pharmaceuticals to Present Data across Growing Oncology Pipeline and Portfolio at ASCO 2024	25/04
The PharmaMar Group presents financial results for the first quarter of 2024	24/04
Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024	17/04
Jazz Pharmaceuticals Completes License Application for FDA for Biliary Tract Cancer Treatment	02/04
Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer	02/04
Jazz Pharmaceuticals : Zanidatamab R&D Day	19/03
Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024	12/03
Agrify Corp Stock Presents Compelling Opportunity As Deal Flow Intensifies ($AGFY)	07/03
Jazz Pharmaceuticals : Corporate Overview	01/03
Tranche Update on Jazz Pharmaceuticals plc's Equity Buyback Plan announced on November 8, 2016.	28/02
Jazz: Q4 Earnings Snapshot	28/02
Jazz Pharmaceuticals Swings to Q4 Non-GAAP Earnings, Revenue Rises; 2024 Guidance Set, Shares Down After Hours	28/02
(JAZZ) JAZZ PHARMACEUTICALS Expects Fiscal Year 2024 EPS Range $18.15 - $19.35	28/02
(JAZZ) JAZZ PHARMACEUTICALS Forecasts Fiscal Year 2024 Revenue $4B-$4.2B	28/02
Earnings Flash (JAZZ) JAZZ PHARMACEUTICALS Reports Q4 EPS $5.02, vs. Street Est of $5.18	28/02
Earnings Flash (JAZZ) JAZZ PHARMACEUTICALS Posts Q4 Revenue $1.01B, vs. Street Est of $1.01B	28/02
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2023 Financial Results and Provides 2024 Financial Guidance	28/02
Jazz Pharmaceuticals plc Provides Earnings Guidance for the Full Year 2024	28/02
Jazz Pharmaceuticals plc Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	28/02
Jazz Pharmaceuticals Appoints Patrick Kennedy to its Board of Directors	27/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Jazz Pharmaceuticals plc

Aandelen

JAZZ

IE00B4Q5ZN47

Andere talen

Filters